

Anders Sonnerborg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6662140/publications.pdf>

Version: 2024-02-01

21
papers

503
citations

687363

13
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

1197
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. <i>Journal of Infectious Diseases</i> , 2015, 211, 1735-1744.	4.0	62
2	Innate lymphoid cell composition associates with COVID-19 disease severity. <i>Clinical and Translational Immunology</i> , 2020, 9, e1224.	3.8	56
3	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	52
4	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	5.8	46
5	All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 2079-2086.	5.8	46
6	Infectivity of SARS-CoV-2: there Is Something More than D614G?. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 574-577.	4.1	44
7	SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. <i>Clinical and Translational Immunology</i> , 2021, 10, e1306.	3.8	36
8	Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase. <i>Pharmaceuticals</i> , 2019, 12, 62.	3.8	30
9	Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. <i>Pathogens</i> , 2020, 9, 320.	2.8	26
10	Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts ≤ 200 Cells/ μ L: TB-HAART Study, a Randomized Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0122587.	2.5	23
11	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2905-2916.	5.8	16
12	Prophylaxis and treatment of HIV-1 infection in pregnancy â€“ Swedish Recommendations 2017. <i>Infectious Diseases</i> , 2018, 50, 495-506.	2.8	14
13	Follow-up of Antiretroviral Treatment in Liver Transplant Recipients with Primary and Chronic HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 13-19.	1.1	13
14	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	8
15	Antiretroviral treatment of HIV infection: Swedish recommendations 2005. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 86-103.	1.5	7
16	Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. <i>Infectious Diseases</i> , 2016, 48, 93-98.	2.8	7
17	Optimal probability weights for estimating causal effects of time-varying treatments with marginal structural Cox models. <i>Statistics in Medicine</i> , 2019, 38, 1891-1902.	1.6	6
18	5th European HIV Drug Resistance Workshop. <i>Future HIV Therapy</i> , 2007, 1, 141-143.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. Open Forum Infectious Diseases, 2022, 9, ofac029.	0.9	3
20	Incidence, treatment and outcome of HIV-associated hematologic malignancies in people living with HIV in Sweden. AIDS Research and Human Retroviruses, 2021, , .	1.1	1
21	Long-Term Outcome of Liver Transplantation in HIV-1-Positive Patients: 15-Year Follow-Up. ISRN Transplantation, 2013, 2013, 1-8.	0.2	1